VIRA THERAPEUTICS
ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.
VIRA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-06-24
Address:
Innsbruck, Tirol, Austria
Country:
Austria
Website Url:
http://www.viratherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+43512272061
Email Addresses:
office(@)viratherapeutics.com
Total Funding:
3.6 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon Google Font API Google Maps Organization Schema PostalAddress Schema Facebook Domain Insights Cookie Consent By Osano
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Hubro Therapeutics
ubro Therapeutics’ vaccines induce cancer specific T cells.
Saiba
Saiba develops cutting-edge therapeutic and prophylactic vaccines.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Employees Featured
Founder
Investors List
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series A - Vira Therapeutics
EMBL Ventures
EMBL Ventures investment in Series A - Vira Therapeutics
austria Wirtschaftsservice (aws)
austria Wirtschaftsservice (aws) investment in Series A - Vira Therapeutics
Official Site Inspections
http://www.viratherapeutics.com Semrush global rank: 15.56 M Semrush visits lastest month: 2
- Host name: 45.223.146.114
- IP address: 45.223.146.114
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vira Therapeutics"
Home · ViraTherapeutics GmbH
ViraT herapeutics develops a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. Our patent protected virus is designed to be safe for human beings and …See details»
Transforming Cancer Therapy | Boehringer Ingelheim US
With a focus on oncolytic viruses, ViraTherapeutics was founded by Prof. Dorothee von Laer, M.D., Head of the Virology Institute at the Medical University of Innsbruck and the inventor of …See details»
Our Partners_ViraTherapeutics | Boehringer Ingelheim
With a focus on oncolytic viruses, ViraTherapeutics was founded by Prof. Dorothee von Laer, M.D., Head of the Virology Institute at the Medical University of Innsbruck and the inventor of the Vesicular Stomatitis Virus Glycoprotein …See details»
BI Acquires All ViraTherapeutics Shares - Boehringer Ingelheim
ViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim’s Discovery Research organization, maintaining its innovative biotech heritage and close …See details»
Vira Therapeutics - Crunchbase Company Profile
Jun 24, 2015 · ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues …See details»
ViraTherapeutics GmbH - LinkedIn
ViraTherapeutics GmbH | 245 followers on LinkedIn. We make cancer immunotherapies more powerful. | ViraTherapeutics develops a new class of immunotherapy drugs based on oncolytic …See details»
ViraTherapeutics Company Profile 2024: Valuation, …
Developer of next-generation oncolytic viral therapy platform created for the treatment of cancer.See details»
PostDoc Oncolytic virotherapy in human tumor ... - ViraTherapeutics
ViraTherapeutics is a subsidiary of the Boehringer Ingelheim group of companies: a perfect symbiosis of big pharma and a biotech start-up vibe. Located in the beautiful city of Innsbruck …See details»
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to …
Sep 13, 2018 · • ViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim’s Discovery Research organization, maintaining its innovative biotech …See details»
Life Sciences Directory: ViraTherapeutics GmbH
ViraTherapeutics develops a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. Our patent protected virus is designed to be safe for human beings and …See details»
Boehringer Ingelheim boosts immune-oncology pipeline through ...
Sep 28, 2016 · ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic virus therapies, has developed its novel technology with joint support from its lead …See details»
Forschung gegen Krebs mit ViraTherapeutics | Boehringer Ingelheim
Was im Jahr 2013 als kleine Spin-Out-Firma der Medizinischen Universität Innsbruck begann, ist nun eine eigenständige Einheit in der Forschungsorganisation von Boehringer Ingelheim. …See details»
Oncodesign announces Drug Discovery Cooperation with …
Under this agreement, Oncodesign will play a key role for Austrian biotech company ViraTherapeutics, handling the preclinical assessment of its immunotherapy programs, which …See details»
Boehringer Ingelheim will Expand ViraTherapeutics' Oncolytic …
Oct 2, 2018 · ViraTherapeutics, headquartered in Innsbruck, Austria, now will operate as a separate unit of Boehringer Ingelheim’s Discovery Research organization, keeping its close …See details»
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to …
Sep 13, 2018 · ViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim’s Discovery Research organization, maintaining its innovative biotech heritage and …See details»
ViraTherapeutics Raises €3.6 Million in the First Closing of a Series …
Jun 24, 2015 · ViraTherapeutics GmbH (ViraT), a privately held biopharmaceutical company developing cancer immunotherapies based on oncolytic (cancer-destroying) viruses, …See details»
Boehringer buys oncolytic virus startup ViraTherapeutics
Sep 13, 2018 · Germany’s Boehringer secured the option to acquire ViraTherapeutics two years ago. That original deal gave Boehringer the chance to work with and potentially buy out …See details»
Strategic-collaboration-with-EnaraBio | Boehringer Ingelheim
Jan 12, 2021 · We are dedicated to collaborating with the oncology community on a shared journey to deliver leading science. Our primary focus is in lung and gastrointestinal cancers, …See details»
Oncolytic virotherapy enhances the efficacy of a cancer vaccine by ...
Oct 1, 2019 · Here, we show that in mouse B16‐OVA melanoma, combination treatment of VSV‐GP with an ovalbumin (OVA) peptide‐loaded dendritic cell (DC) vaccine (DCVacc) …See details»
Life Sciences Directory: Arthro Kinetics Biotechnology GmbH
Arthro Kinetics Biotechnology GmbH: We develop, manufacture and distribute medical implants based on a proprietary and unique 3D Biomatrix from collagen type 1, which functions as a …See details»